Search

Author/Creator Gogas, Helen

1. 301 Association of response with survival outcomes with atezolizumab in combination with vemurafenib and cobimetinib in the phase 3 IMspire150 study. (9th November 2020)

Authors:
Ascierto, Paolo; Lewis, Karl; Robert, Caroline; Stroyakovskiy, Daniil; Gogas, Helen; Protsenko, Svetlana; Pereira, Rodrigo; Eigentler, Thomas; Rutkowski, Piotr; Demidov, Lev; Manikhas, Georgy Moiseevich; Li, Haocheng; Zhu, Qian; McKenna, Edward; McNally, Virginia; Gutzmer, Ralf; McArthur, Grant
Journal:
Journal for immunotherapy of cancer
Issue:
Volume 8(2020)Supplement 3
Page Start:
A328
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. Acquired BRAF inhibitor resistance: A multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms. Issue 18 (December 2015)

Authors:
Johnson, Douglas B.; Menzies, Alexander M.; Zimmer, Lisa; Eroglu, Zeynep; Ye, Fei; Zhao, Shilin; Rizos, Helen; Sucker, Antje; Scolyer, Richard A.; Gutzmer, Ralf; Gogas, Helen; Kefford, Richard F.; Thompson, John F.; Becker, Jürgen C.; Berking, Carola; Egberts, Friederike; Loquai, Carmen; Goldinge...
Journal:
European journal of cancer
Issue:
Volume 51:Issue 18(2015:Dec.)
Page Start:
2792
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

6. Adjuvant nivolumab versus ipilimumab (CheckMate 238 trial): Reassessment of 4-year efficacy outcomes in patients with stage III melanoma per AJCC-8 staging criteria. (September 2022)

Authors:
Larkin, James; Weber, Jeffrey; Del Vecchio, Michele; Gogas, Helen; Arance, Ana M.; Dalle, Stephane; Cowey, C. Lance; Schenker, Michael; Grob, Jean-Jacques; Chiarion-Sileni, Vanna; Márquez-Rodas, Iván; Butler, Marcus O.; Di Giacomo, Anna Marie; Middleton, Mark R.; De la Cruz-Merino, Luis; Arenberg...
Journal:
European journal of cancer
Issue:
Volume 173(2022)
Page Start:
285
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

7. Adjuvant nivolumab versus ipilimumab in resected stage IIIB–C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial. Issue 11 (November 2020)

Authors:
Ascierto, Paolo A; Del Vecchio, Michele; Mandalá, Mario; Gogas, Helen; Arance, Ana M; Dalle, Stephane; Cowey, C Lance; Schenker, Michael; Grob, Jean-Jacques; Chiarion-Sileni, Vanna; Márquez-Rodas, Iván; Butler, Marcus O; Maio, Michele; Middleton, Mark R; de la Cruz-Merino, Luis; Arenberger, Petr;...
Journal:
Lancet oncology
Issue:
Volume 21:Issue 11(2020)
Page Start:
1465
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

8. Adjuvant Therapy of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Patients With Resected Stage IIIB-D or Stage IV Melanoma (CheckMate 915). Issue 3 (26th September 2022)

Authors:
Weber, Jeffrey S.; Schadendorf, Dirk; Del Vecchio, Michele; Larkin, James; Atkinson, Victoria; Schenker, Michael; Pigozzo, Jacopo; Gogas, Helen; Dalle, Stéphane; Meyer, Nicolas; Ascierto, Paolo A.; Sandhu, Shahneen; Eigentler, Thomas; Gutzmer, Ralf; Hassel, Jessica C.; Robert, Caroline; Carlino, ...
Journal:
Journal of clinical oncology
Issue:
Volume 41:Issue 3(2023)
Page Start:
517
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗